Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 10 de 10
Filter
1.
Einstein (Sao Paulo) ; 18: eAE4799, 2020.
Article in English, Portuguese | MEDLINE | ID: mdl-32215466

ABSTRACT

The Brazilian Consensus on Nutrition in Hematopoietic Stem Cell Transplantation: Graft- versus -host disease was approved by Sociedade Brasileira de Transplante de Medula Óssea , with the participation of 26 Brazilian hematopoietic stem cell transplantation centers. It describes the main nutritional protocols in cases of Graft- versus -host disease, the main complication of hematopoietic stem cell transplantation.


Subject(s)
Consensus Development Conferences as Topic , Graft vs Host Disease/diet therapy , Graft vs Host Disease/etiology , Hematopoietic Stem Cell Transplantation/adverse effects , Nutrition Therapy/standards , Nutritional Requirements , Brazil , Congresses as Topic , Gastrointestinal Diseases/diet therapy , Gastrointestinal Diseases/etiology , Gastrointestinal Diseases/physiopathology , Graft vs Host Disease/physiopathology , Humans , Nutrition Therapy/methods , Severity of Illness Index
2.
Einstein (Säo Paulo) ; 18: eAE4799, 2020. tab, graf
Article in English | LILACS | ID: biblio-1090073

ABSTRACT

ABSTRACT The Brazilian Consensus on Nutrition in Hematopoietic Stem Cell Transplantation: Graft- versus -host disease was approved by Sociedade Brasileira de Transplante de Medula Óssea , with the participation of 26 Brazilian hematopoietic stem cell transplantation centers. It describes the main nutritional protocols in cases of Graft- versus -host disease, the main complication of hematopoietic stem cell transplantation.


RESUMO O Consenso Brasileiro de Nutrição no Transplante de Células Tronco Hematopoiéticas: doença do enxerto contra o hospedeiro foi aprovado pela Sociedade Brasileira de Transplante de Medula Óssea, com a participação de 26 centros brasileiros de transplante de células-tronco hematopoiéticas. O Consenso descreve as principais condutas nutricionais em casos de doença do enxerto contra o hospedeiro, a principal complicação do transplante de células-tronco hematopoiéticas.


Subject(s)
Consensus Development Conferences as Topic , Hematopoietic Stem Cell Transplantation/adverse effects , Nutrition Therapy/standards , Graft vs Host Disease/diet therapy , Graft vs Host Disease/etiology , Nutritional Requirements , Severity of Illness Index , Brazil , Congresses as Topic , Nutrition Therapy/methods , Gastrointestinal Diseases/diet therapy , Gastrointestinal Diseases/etiology , Gastrointestinal Diseases/physiopathology , Graft vs Host Disease/physiopathology
4.
Transfusion ; 58(11): 2495-2500, 2018 11.
Article in English | MEDLINE | ID: mdl-30291766

ABSTRACT

BACKGROUND: Extracorporeal photopheresis (ECP) has been established to treat graft-versus-host disease. Our mini ECP technique (mini-ECP) allows for treatment of patients with GVHD and contraindications for classical ECP or low body weight. The safety and efficacy of applying ECP for the long-term treatment of chronic GVHD (cGVHD) have not been described. STUDY DESIGN AND METHODS: A retrospective analysis of mini-ECP treatments for children and adolescents with cGVHD was performed. Mini-ECP with 100 to 200 mL of whole blood was used to treat 14 patients. The median age at the start of treatment was 7 years (range, 1-17 years), and median body weight was 20 kg (range, 8-53 kg). A total of 703 mini-ECP treatments was performed. The median number of treatments per patient was 35 (range, 8-129), and median treatment duration was 11 months (range, 1.4-28.5 months). RESULTS: Mini-ECP was well tolerated. Four adverse events occurred in three patients, and two of them were related to the ECP procedure. Complete or partial responses were observed in 10 patients. Steroids were discontinued in seven patients and tapered in three others. Responses were seen in the skin, mouth, gastrointestinal tract, and eyes. CONCLUSION: Mini-ECP represents a less invasive ECP alternative for low-body-weight patients with cGVHD and contraindications for apheresis.


Subject(s)
Graft vs Host Disease/therapy , Photopheresis/methods , Adolescent , Blood Component Removal/methods , Body Weight/physiology , Child , Child, Preschool , Female , Graft vs Host Disease/diet therapy , Humans , Immunosuppressive Agents/therapeutic use , Infant , Male , Retrospective Studies
5.
Acta pediatr. esp ; 75(11/12): 122-126, nov.-dic. 2017. tab
Article in Spanish | IBECS | ID: ibc-170222

ABSTRACT

El enfermo oncológico es un paciente con alto riesgo de desnutrición. En este tipo de pacientes es prioritario el diseño de un soporte nutricional personalizado y precoz para conseguir una mejor tolerancia al tratamiento, una buena evolución en su enfermedad de base y una mejora de su calidad de vida. La nutrición parenteral queda reservada para cortos periodos en los que surgen complicaciones importantes durante la quimioterapia y la radioterapia (mucositis, enteritis...), pero es esencial en el trasplante de progenitores hematopoyéticos, así como en su complicación más importante, la enfermedad de injerto contra huésped, en que puede prolongarse durante largos periodos de tiempo. Es fundamental el conocimiento de las alteraciones metabólicas que tienen lugar, así como las variaciones en el gasto energético en reposo y la composición corporal para ajustar los aportes de forma segura y eficaz, minimizando las complicaciones (AU)


The oncological patient is at high risk of malnutrition. Early and personalized nutritional support is essential to improve tolerance to chemotherapy and achieve a better outcome and quality of life. Parenteral nutrition is usually reserved for short periods with major complications during chemotherapy and radiotherapy (mucositis, enteritis...) but it becomes essential in hematopoietic stem cell transplantation as well as in graftversushost disease. The knowledge of the metabolic alterations is essential, as well as the variations in resting energy expenditure and body composition to adjust the requierements in a safe and effective way, minimizing complications (AU)


Subject(s)
Humans , Child , Parenteral Nutrition/methods , Neoplasms/diet therapy , Hematopoietic Stem Cell Transplantation , Neoplasms/complications , Erythroid Precursor Cells/transplantation , Graft vs Host Disease/diet therapy , Malnutrition/diet therapy , Nutritional Support/methods
6.
Clin Transplant ; 31(5)2017 05.
Article in English | MEDLINE | ID: mdl-28256022

ABSTRACT

Graft-versus-host disease (GVHD) is a major adverse effect associated with allogeneic stem cell transplant. Previous studies in mice indicated that administration of the probiotic Lactobacillus rhamnosus GG can reduce the incidence of GVHD after hematopoietic stem cell transplant. Here we report results from the first randomized probiotic enteric regimen trial in which allogenic hematopoietic stem cell patients were supplemented with Lactobacillus rhamnosus GG. Gut microbiome analysis confirmed a previously reported gut microbiome association with GVHD. However, the clinical trial was terminated when interim analysis did not detect an appreciable probiotic-related change in the gut microbiome or incidence of GVHD. Additional studies are necessary to determine whether probiotics can alter the incidence of GVHD after allogeneic stem cell transplant.


Subject(s)
Gastrointestinal Microbiome/drug effects , Graft vs Host Disease/etiology , Hematopoietic Stem Cell Transplantation/adverse effects , Lacticaseibacillus rhamnosus/physiology , Probiotics/administration & dosage , Adult , Aged , Female , Follow-Up Studies , Graft vs Host Disease/diet therapy , Humans , Male , Middle Aged , Prognosis , Transplantation, Homologous
7.
JPEN J Parenter Enteral Nutr ; 41(8): 1286-1292, 2017 11.
Article in English | MEDLINE | ID: mdl-27503936

ABSTRACT

INTRODUCTION: Graft-versus-host disease (GVHD) is a serious complication of bone marrow transplantation (BMT), requiring higher doses of glucocorticoids or immunosuppressive therapies and further straining transplant recipients. Immunonutrition, such as vitamins and amino acid supplements, increase immunity and decrease inflammation and oxidative stress. This meta-analysis examines the impact of immunonutrition on the incidence of GVHD and postoperative infections among BMT recipients. METHODS: A comprehensive literature search for all published randomized controlled trials was conducted with PubMed, Cochrane Central Registry of Controlled Trials, and Google Scholar (1966-2016). Keywords in the search included variations of terms related to immunonutrition, such as "vitamin," "glutamine," and "transplant." Outcomes included incidence of GVHD and infection. RESULTS: Ten randomized controlled trials involving 681 BMT recipients were analyzed: 332 receiving immunonutrition and 349 receiving standard nutrition. Immunonutrition is correlated with a decreased incidence of GVHD by 19% (relative risk [RR] = 0.810, 95% CI: 0.695-0.945, P = .007). There was no significant difference in the incidence of infections with immunonutrition (RR = 1.016, 95% CI: 0.819-1.261, P = .885). Subgroup analysis of glutamine compared with N-acetylcysteine, selenium, and eicosapentaenoic acid showed no significant difference in the incidence of GVHD or infections (RR = 0.913, 95% CI: 0.732-1.139, P = .419; RR = 0.951, 95% CI: 0.732-1.235; P = .708, respectively). CONCLUSION: The use of immunonutrition is associated with a reduced risk of GVHD in BMT recipients, potentially as a result of improved immune support and free radical scavenging. Providing immunonutrient supplements is a valuable adjunct in the routine care of BMT recipients, helping to alleviate a common and deadly complication.


Subject(s)
Bone Marrow Transplantation/adverse effects , Dietary Supplements , Graft vs Host Disease/diet therapy , Graft vs Host Disease/prevention & control , Postoperative Complications/diet therapy , Humans , Incidence , Postoperative Complications/prevention & control , Randomized Controlled Trials as Topic , Risk Factors
8.
Turk J Pediatr ; 58(2): 145-151, 2016.
Article in English | MEDLINE | ID: mdl-27976554

ABSTRACT

Gastrointestinal tract is one of the major systems affected by graft-versus-host disease (GVHD). Injury to the gut during conditioning therapy before stem-cell transplantation (SCT) plays a pivotal role in the initiation of inflammatory stimuli. We reviewed medical records of the patients who underwent SCT between April 2010 and June 2013 in our center. A stepwise upgrade diet was given to the children with acute GI-GVHD (Gastrointestinal GVHD) including parenteral and enteral nutrition. A total of 105 patients underwent SCT and seven patients developed grade III-IV acute GI-GVHD. Total parenteral nutrition (TPN) was initiated to all patients after the diagnosis of GI-GVHD and minimal enteral nutrition (1-2 ml/kg/day standard pediatric enteral formula/special meat soup) was given to the patients. GI-GVHD improved in all patients with no change in body weight, and recovery to a normal diet took 10-30 days. Stepwise diet management of oral nutrition contributed to rapid improvement of grades III-IV acute GI-GVHD.


Subject(s)
Gastrointestinal Diseases/diet therapy , Graft vs Host Disease/diet therapy , Hematopoietic Stem Cell Transplantation/adverse effects , Parenteral Nutrition/methods , Adolescent , Child , Child, Preschool , Diet , Female , Gastrointestinal Diseases/etiology , Humans , Male
9.
Oncol Res Treat ; 38(5): 239-43, 2015.
Article in English | MEDLINE | ID: mdl-25966771

ABSTRACT

Acute graft-versus-host disease (GvHD) is mediated by alloreactive donor-derived T cells with a suitable T cell receptor recognizing recipient major histocompatibility complex or minor histocompatibility antigens. However, the process of T cell activation and tissue injury sensing is also dependent on innate immune cells and non-hematopoietic cells. Different cell types of the innate immune system have the ability to sense danger-associated and pathogen-associated molecular patterns via pattern recognition receptors which can be transmembrane Toll-like receptors or cytoplasmic nucleotide-binding oligomerization domain-like receptors. Infectious stimuli include bacterial, viral, and fungal components, while non-infectious stimuli can be components derived from damaged cells or extracellular matrix. A better understanding of the complex sensing and effector mechanisms of innate immune cells in GvHD may help to improve preventive and therapeutic strategies in GvHD.


Subject(s)
Graft vs Host Disease/immunology , Immunity, Innate/physiology , Adenosine/metabolism , Graft vs Host Disease/diet therapy , Graft vs Host Disease/prevention & control , Humans
10.
Article in English | MEDLINE | ID: mdl-8415805

ABSTRACT

One of the mechanisms by which corticosteroids may modify acute graft vs host disease (GvHD) is via inhibition of arachidonic acid (AA) metabolism. Leukotriene B4 (LTB4) is a product of that pathway which may take part in the pathogenesis of GvHD through the stimulation of T-lymphopoiesis and T-lymphocyte activation. LTB4 is a metabolite of AA (20:4n-6). Alternate dietary sources of polyunsaturated fatty acids (PUFA), specifically eicosapenteinoic acid (20:5n-3) (EPA) and docosahexaenoic acid (22:6n-3) (DHA), shift the LTs formed with a decrease in LTB4 an increase in LTB5. LTB5 is a less potent agonist than LTB4 and this results in a theoretical decrease of LTB4 mediated events. Supplementation of in vitro bone marrow cultures with EPA or DHA had no detrimental effect on myeloid colony formation. Dietary EPA/DHA supplementation in mice with induced GvHD appeared to be safe and well tolerated. The LTB4:LTB5 ratio shifted from 7.65 +/- 1.75 in control-fed animals to 1.03 +/- 0.18. Fish-oil-supplementation did not compromise engraftment or stem cell content. Alone, this therapy was unable to modify GvHD.


Subject(s)
Fish Oils/pharmacology , Graft vs Host Disease/diet therapy , Graft vs Host Disease/immunology , Leukotriene B4/metabolism , Animals , Arachidonic Acid/pharmacology , Bone Marrow/drug effects , Disease Models, Animal , Docosahexaenoic Acids/pharmacology , Eicosapentaenoic Acid/pharmacology , Fish Oils/therapeutic use , Graft vs Host Disease/metabolism , Granulocyte-Macrophage Colony-Stimulating Factor/drug effects , Humans , In Vitro Techniques , Lipoxygenase/metabolism , Mice , Mice, Inbred C57BL , Mice, Inbred CBA , Spleen/drug effects , T-Lymphocytes/drug effects
SELECTION OF CITATIONS
SEARCH DETAIL
...